Effects of mutant c-Kit in early myeloid cells (vol 34, pg 451, 1997)

被引:20
作者
Ashman, LK [1 ]
Ferrao, P [1 ]
Cole, SR [1 ]
Cambareri, AC [1 ]
机构
[1] Hanson Ctr Canc Res, Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia
关键词
mutant c-Kit; early myeloid cells; transformation;
D O I
10.3109/10428190009057652
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activating mutations in c-Kil, the receptor for Stem Cell Factor (SCF), have been identified in dysplasias and leukaemias of the mast cell lineage and have been shown to contribute to transformation in model systems. Early myeloid cells also normally express c-Kit and their survival, proliferation and differentiation is promoted by SCE It might therefore be expected that c-Kit mutations could also be involved in some acute and/or chronic myeloid leukaemias. We have found that mutant c-Kit (and normal c-Kit in the presence of SCF) provides a strong differentiation stimulus in normal and immortalised murine early myeloid cells. Since maturation of haemopoietic cells, with the exception of mast cells, results in down-regulation of c-Kit expression, the transforming effects of mutant receptor may be self-limiting in most lineages. This is consistent with the observation that multipotential progenitor cells from some patients with systemic mastocytosis express mutant c-Kit. However, c-Kit mutations have been observed in a few cases of myelodysplastic syndromes or AML without mast cell features. Oncogenesis involves multiple genetic changes and the phenotype of malignant haemopoietic cells expressing mutant c-Kit may be influenced by co-oncogenic events. For example mutations blocking the differentiative effect of mutant c-Kit might result in AML rather than mastocytosis. Thus the extent to which c-Kit mutations contribute to malignancies of early myeloid phenotype remains unknown, and resolution of this issue is complicated by the heterogeneity of this family of diseases.
引用
收藏
页码:233 / 243
页数:11
相关论文
共 91 条
[41]  
HUANG CY, 1992, NAT PROD LETT, V1, P3
[42]  
HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0
[43]  
IKEDA H, 1991, BLOOD, V78, P2962
[44]  
IRANI AMA, 1992, BLOOD, V80, P3009
[45]  
KEES UR, 1995, LEUKEMIA, V9, P1046
[46]   C-kit point mutation in patients with myeloproliferative disorders [J].
Kimura, A ;
Nakata, Y ;
Katoh, O ;
Hyodo, H .
LEUKEMIA & LYMPHOMA, 1997, 25 (3-4) :281-287
[47]   CONSTITUTIVELY ACTIVATING MUTATIONS OF C-KIT RECEPTOR TYROSINE KINASE CONFER FACTOR-INDEPENDENT GROWTH AND TUMORIGENICITY OF FACTOR-DEPENDENT HEMATOPOIETIC-CELL LINES [J].
KITAYAMA, H ;
KANAKURA, Y ;
FURITSU, T ;
TSUJIMURA, T ;
ORITANI, K ;
IKEDA, H ;
SUGAHARA, H ;
MITSUI, H ;
KANAYAMA, Y ;
KITAMURA, Y ;
MATSUZAWA, Y .
BLOOD, 1995, 85 (03) :790-798
[48]  
Kitayama H, 1996, BLOOD, V88, P995
[49]   SPECIFIC RECRUITMENT OF SH-PTP1 TO THE ERYTHROPOIETIN RECEPTOR CAUSES INACTIVATION OF JAK2 AND TERMINATION OF PROLIFERATIVE SIGNALS [J].
KLINGMULLER, U ;
LORENZ, U ;
CANTLEY, LC ;
NEEL, BG ;
LODISH, HF .
CELL, 1995, 80 (05) :729-738
[50]  
Krystal GW, 1996, CANCER RES, V56, P370